PERCEPTIVE ADVISORS LLC - 19 May 2023 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role
10%+ Owner
Signature
/s/ Perceptive Advisors LLC, By: Joseph Edelman, its managing member
Issuer symbol
SLNO
Transactions as of
19 May 2023
Transactions value $
$406,075
Form type
4
Filing time
23 May 2023, 18:47:52 UTC
Previous filing
18 May 2023
Next filing
26 May 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLNO Common Stock Purchase $116,424 +25,200 +1.35% $4.62* 1,889,655 19 May 2023 See footnotes F1, F4
transaction SLNO Common Stock Purchase $139,776 +27,300 +1.44% $5.12* 1,916,955 22 May 2023 See footnotes F2, F4
transaction SLNO Common Stock Purchase $149,875 +27,500 +1.43% $5.45* 1,944,455 23 May 2023 See footnotes F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.50 to $4.84, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported.
F2 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.00 to $5.161, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported.
F3 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.396 to $5.4739, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported.
F4 The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.